|
Session 32
Plenary
Toward Broadly Neutralizing Antibodies against HIV and Advances in HIV Vaccine Development
Tuesday, 4 - 5:20 pm
Room: West Hall B |
| 4:00 pm 99 |
Toward Broadly Neutralizing Antibodies against HIV
Dennisq Burton
Scripps Res Inst, La Jolla, CA, US |
| 4:30 pm 100 |
HVTN Experience with NIAID’s Vaccine Research Center’s Multiclade, Multigene Preventive HIV Vaccine Approach
Michael Keefer*1, C Morgan2, L Peiperl3, J McElrath2, Z Moodie2, P Wright4, A Duerr2, B Graham5, G Nabel5, L Corey2, and for the NIAID HIV Vaccine Trials Network
1Univ of Rochester, NY, US; 2Fred Hutchinson Cancer Res Ctr, Seattle, WA, US; 3San Francisco Dept of Publ Hlth, CA, US; 4Vanderbilt Univ, Nashville, TN, US; and 5Vaccine Res Ctr, NIAID, NIH, Bethesda, MD, US |
4:45 pm 101
 |
EV02, a Phase I Trial to Assess the Safety and Immunogenicity of DNA-C followed by NYVAC-C in an Open, Randomized Comparison to NYVAC-C Alone in Healthy Volunteers at Low Risk of HIV Infection
Pierre-Alexandre Bart*1, A Harari1, C Cellerai1, D Ciuffreda1, T Barber2, W Stöhr3, S McCormack3, G Pantaleo1, J Weber2, and EUROVACC Prgm
1Ctr Hosp Univ Vaudois Lausanne, Switzerland; 2Imperial Coll, London, UK; and 3Med Res Council Clin Trials Unit, London, UK |
| 5:00 pm 102 |
Safety and Immunogenicity of the VRC Recombinant Multiclade HIV-1 Adenoviral Vector Vaccine Alone or in Combination with the VRC Multiclade HIV-1 DNA Plasmid Vaccine in Healthy African Adults
Kayitesi Kayitenkore*1, G Omosa-Manyonyi2, J Bwayo2, E Karita1, W Jaoko2, C Schmidt3, J Gilmour3, M Boaz3, S Than3, and B Graham4
1Rwanda Zambia HIV Res Group, Kigali and Lusaka; 2Kenya AIDS Vaccine Initiative, Nairobi; 3Intl AIDS Vaccine Initiative, New York, NY, US and Nairobi, Kenya; and 4Vaccine Res Ctr, NIAID, NIH, Bethesda, MD, US |
| 5:15 pm 103 |
Scientific Overview: Status of HIV Vaccine Efficacy Trials
Merlin Robb
US Military HIV Res Prgm, Rockville, MD, US |
|
